The AmpliSeq for Illumina sequencing solution offers a highly multiplexed polymerase chain reaction (PCR)-based workflow for use with targets ranging from a few to hundreds of genes in a single run. AmpliSeq for Illumina panels are optimized for clinical cancer research and genetic disease studies.

TruSight Tumor 26

This targeted sequencing panel enables clinical researchers to identify low-frequency variation in solid tumors across 26 genes.Read More...
Select Product(s)

TruSight Tumor 26

FC-130-2001

Price
 
 
Accessory Products
What accessories do I need?

TruSeq Custom Amplicon Filter Plate (1 plate)

FC-130-1006

Price
 
 

TruSeq Index Plate Fixture & Collar Kit (2 each)

FC-130-1007

Price
 
 

Product Highlights

TruSight Tumor 26 takes a deeper view of variation in solid tumors including lung, colon, melanoma, gastric and ovarian. This enables clinical researchers to identify low-frequency variation across 26 genes for a more comprehensive view of somatic variation.

  • Highly accurate variant analysis at limit of detection below 5% variant allele frequency across 174 amplicons, with 1000x minimum coverage of each region
  • Exceptional sample success rates with minimal DNA input for accurate base calling, even in degraded FFPE samples
  • Coverage of complete exons for analysis of molecular heterogeneity in highly relevant content selected from CAP1 and NCCN2 guidelines, and late stage clinical trials3

This panel provides amplicon-based library preparation reagents, DNA QC, sample indexes, and oligos targeting identified regions of interest.

Genes in TruSight Tumor 26

See which solid tumor-related genes are represented in TruSight Tumor 26. View Gene List.

See All Illumina Cancer Research Panels

Specifications

Method-Specific Workflow Example(s)

 

Supporting Data and Figures

TruSight Tumor 26 Workflow
TruSight Tumor 26 example workflow image

TruSight Tumor 26 is a comprehensive assay for examining relevant cancer genes involved in solid tumors, even in challenging FFPE samples.

 
TruSight Tumor 26 Gene List
AKT1 EGFR GNAS NRAS STK11
ALK ERBB2 KIT PDGFRA TP53
APC FBXW7 KRAS PIK3CA  
BRAF FGFR2 MAP2k1 PTEN  
CDH1 FOXL2 MET SMAD4  
CTNNB1 GNAQ MSH6 SRC  

Scientific Posters

AMP 2013

A multi-institutional study: Evaluation of a novel technique that uses strand-specific information to increase accuracy in a next-generation sequencing assay to identify somatic DNA variants.

View Poster

ASCO 2013

A novel approach that improves detection of somatic DNA variants in solid tumors by next-generation sequencing from FFPE samples.

View Poster

ESHG 2013

A novel technique that distinguishes low-level somatic DNA variants from FFPE-induced artifacts in solid tumors by next-generation sequencing (NGS).

View Poster

Related Products

References
  1. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, et al. 2013 Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. Archives of Pathology & Laboratory Medicine Vol 137 Issue 4
  2. NCCN
  3. Clinical Trials
  4. Davies, Kurtis D., et al. "Multi-Institutional FASTQ File Exchange as a Means of Proficiency Testing for Next-Generation Sequencing Bioinformatics and Variant Interpretation." The Journal of Molecular Diagnostics 2016

Note regarding biomarker patents and other patents unique to specific uses of products: Some genomic variants, including some nucleic acid sequences, and their use in specific applications may be protected by patents. Customers are advised to determine whether they are required to obtain licenses from the party that owns or controls such patents in order to use the product in customer's specific application.